Regulation of drugs for children in Europe
- 13 December 2007
- Vol. 335 (7632) , 1221-1222
- https://doi.org/10.1136/bmj.39400.376424.be
Abstract
New legislation encourages the drug industry to produce high quality transparent research Over the past 10 years, studies have shown widespread use of unlicensed and off-label drugs to treat children in hospital and in the community.1 2 A prospective European study showed that two thirds of children in hospital received at least one unlicensed or off-label drug, and almost half of all drug prescriptions for these children were either unlicensed or off label.1 Subsequent studies confirmed that the use of unlicensed and off-label drugs is more likely to be associated with drug toxicity.3 In 1999, concerns were raised about children in Europe receiving unlicensed or off-label drugs instead of ones that have been scientifically evaluated and licensed.4 In December 2006, after extensive consultation, the European parliament approved legislation that should improve the regulation of drug treatment for children (regulation number 1901/2006 on medicinal products for paediatric use). The legislation aims to ensure that drugs used for children are subject to high quality …Keywords
This publication has 7 references indexed in Scilit:
- Stimulation programs for pediatric drug research – do children really benefit?European Journal of Pediatrics, 2007
- Potential tenfold drug overdoses on a neonatal unitArchives of Disease in Childhood: Fetal & Neonatal, 2004
- Training in paediatric clinical pharmacology in the UKBritish Journal of Clinical Pharmacology, 2004
- Incidence of adverse drug reactions in paediatric in/out‐patients: a systematic review and meta‐analysis of prospective studiesBritish Journal of Clinical Pharmacology, 2001
- Unlicensed and off label prescribing of drugs in general practiceArchives of Disease in Childhood, 2000
- Survey of unlicensed and off label drug use in paediatric wards in European countriesBMJ, 2000
- Closing the gap in drug therapyThe Lancet, 1999